Bicara Therapeutics (NASDAQ:BCAX) Trading Up 5.7% – What’s Next?

Bicara Therapeutics Inc. (NASDAQ:BCAX)’s share price was up 5.7% on Thursday . The stock traded as high as $13.66 and last traded at $13.85. Approximately 26,971 shares traded hands during mid-day trading, a decline of 94% from the average daily volume of 457,999 shares. The stock had previously closed at $13.10.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Wedbush restated an “outperform” rating and set a $31.00 price target on shares of Bicara Therapeutics in a research note on Thursday. Cantor Fitzgerald reiterated an “overweight” rating and set a $13.01 price target on shares of Bicara Therapeutics in a research note on Thursday, March 13th. Finally, HC Wainwright lifted their price objective on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, January 27th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $36.50.

Bicara Therapeutics Price Performance

The stock’s 50 day moving average is $13.04.

Bicara Therapeutics (NASDAQ:BCAX) last posted its quarterly earnings results on Thursday, March 27th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.08). As a group, analysts predict that Bicara Therapeutics Inc. will post -2.59 EPS for the current year.

Institutional Investors Weigh In On Bicara Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of BCAX. California State Teachers Retirement System bought a new position in shares of Bicara Therapeutics during the fourth quarter valued at approximately $25,000. Spire Wealth Management bought a new position in Bicara Therapeutics during the 4th quarter worth $31,000. BNP Paribas Financial Markets acquired a new stake in Bicara Therapeutics in the fourth quarter worth $32,000. Legal & General Group Plc bought a new stake in Bicara Therapeutics in the fourth quarter valued at $33,000. Finally, Summit Investment Advisors Inc. acquired a new position in shares of Bicara Therapeutics during the fourth quarter valued at $35,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.